Upcoming US approval verdicts include inclisiran, valrox and risdiplam, but toxicity issues could scupper filgotinib.
Biopsy data set up efruxifermin as a strong contender in the race to find an effective Nash treatment.
Digital health is a core focus for Philips. Might more acquisitions be on the way?
Suddenly 2020’s medtech M&A landscape looks very different.
As Smiths Group delays its split partly so it can focus on ventilator production, the US FDA grants emergency authorisation to other breathing devices to treat Covid-19.